Nothing new, but thank you for the DD. If anything, Shire is moving at your typical corporate pace in making decisions about it, but it's at least a good sign that the trial ended 10 months ago and they still consider it part of the pipeline.
Personally I think the recent activity coincides more suspiciously with the wrapping up of the Prizer ponezumab trial for CAA. I'm guessing we hear something about that trail in the next month or two.
It's strange that they would be sitting on it IF the data is as good as deals claims. Also, why would Shire engage ilns before completion of the trial, according to deals they had meets last year.
Something has to be going on and it's not Shire just sitting on the Data. There are others trying to be there first to market for FA
Market Data 
Markets 
AI
